February 6, 2005: Headlines: COS - Brazil: Medicine: Patient Assistance Program: Healthy Skepticism: Brazil RPCV Joana Ramo writes "New Definition of “Patient Assistance Program” in Brazil"

Peace Corps Online: Peace Corps News: Peace Corps Library: Medicine: January 23, 2005: Index: PCOL Exclusive: Medicine : February 6, 2005: Headlines: COS - Brazil: Medicine: Patient Assistance Program: Healthy Skepticism: Brazil RPCV Joana Ramo writes "New Definition of “Patient Assistance Program” in Brazil"

By Admin1 (admin) (pool-151-196-123-27.balt.east.verizon.net - on Wednesday, March 09, 2005 - 3:49 am: Edit Post

Brazil RPCV Joana Ramo writes "New Definition of “Patient Assistance Program” in Brazil"

Brazil RPCV Joana Ramo writes New Definition of “Patient Assistance Program” in Brazil

Brazil RPCV Joana Ramo writes "New Definition of “Patient Assistance Program” in Brazil"

New Definition of “Patient Assistance Program” in Brazil
By: Joana Ramos
Healthy Skepticism International News 2005 Jan; 23: 1

Joana Ramos of Seattle is an independent consultant in oncology social work. Also trained as a medical interpreter, she is a former resident of Brazil.

Joana Ramos, MSW
Cancer Resources & Advocacy
Seattle Washington USA

The term “ patient assistance program” (PAP) usually means a program whereby patients with limited resources and/or little or no insurance cover for prescription medicines, may receive a drug from the manufacturer at no or reduced cost. They are most common in the USA where no universal health system exists. Pharmas operating here like to boast of their generosity in offering PAPs, which usually require complex application procedures with rigid eligibility criteria. With effort, some patients do succeed in receiving medicines this way, and the existence of PAPs acts as yet another strategy of the drug companies to try to stave off governmental price controls. When Novartis gained FDA approval for Glivec (Gleevec in the USA) in May of 2001, company CEO Vasella went on public record saying the company was establishing both US and international versions of a PAP so that no patient in need of the drug ( for which a global price was set) would be denied access for financial reasons. The current scenario in Brazil which will be discussed in this article, is part of the larger picture of the convoluted and problematic access to a new cancer drug that is both revolutionary in its effectiveness and extraordinarily expensive.[1] The case of Glivec is a critical one to consider in terms of worldwide access to medicines.

Glivec PAP in Brazil
Novartis Brazil has put a whole new spin on the meaning of Patient Assistance Program ( PAP - conveniently this acronym happens to be equivalent in both Portuguese and English) with the creation of a so-called PAP for Glivec. in that country. The company website serves as the vehicle for informing physicians about this service being offered to their patients. I share with you here a synopsis in English of the company’s offering, (a copy of the original in Portuguese may be found at the end of the article) accompanied by commentary on the context of the program.

Author’s note: While preparing this article, access to the information about the Glivec PAP on the Novartis Brazil website underwent a change. Since I had last viewed the site on 12 August 2004, access to the PAP page has been restricted to only those providing their Brazilian medical professional registration data. Formerly the page was accessible on the public version of the site, www.glivec.com.br. By 25 August, I was only able to access it via Google’s cached version, as cited below.

The letter to physicians on the company website emphasizes how informing patients about the PAP will not only ensure that the patients’ psychosocial needs are met, but will result in better treatment outcomes. Physicians are urged to share this important information with patients already on Glivec as well as with newly-diagnosed patients for whom the treatment is being prescribed. The letter goes on to state that the support and caring that cancer patients need so much will be offered by the personnel of the Glivec hotline via a toll-free telephone number. However, no details are given about the training and credentials of those who will answer the calls, who are described as offering both treatment information and psychosocial support to patients.

All that the doctors need to do is to give the patient a copy of their prescription for Glivec along with a special “PAP Glivec” card which looks like a credit card and is supplied by the Novartis drug reps. (An image is shown on the webpage). The patient, in turn, needs to fax the prescription to Novartis, and then call the hotline to provide their personal information and contact details for their physician. After the data is verified and the patient is registered in the PAP, a special Glivec Patient Information Kit, consisting of a tote bag, educational video, and a brochure will be sent to the patient’s home. Registered patients may then call the hotline to get answers to their questions about treatment with Glivec and possible side effects.

DTCA of prescription drugs is strictly prohibited in Brazil,[2] and promotional materials and advertising may only be directed to physicians, and in some cases, to pharmacists. Therefore there is an incentive to pharma to find other ways of reaching consumers, hence the format and rationale of this pitch for a “PAP Glivec.”

In other words, through this web-based advertising campaign, Novartis gains direct access to patients and attempts to generate good-will and build brand loyalty among them. The patient gets nothing besides a cloth tote bag, the video and brochure, and a phone number to call with questions. It is as yet unclear how this promotion stands in terms of Brazil’s legal prohibition of DTCA. Theoretically, it might be rationalized that since the “PAP” targets only patients to whom Glivec has been prescribed, it is not technically advertising to the “public.” However, if a patient used the tote bag in public, then it might be considered to be a form of advertising. A legal opinion would be needed to evaluate whether Novartis is violating the intent of the law.

Some background
This PAP offering is quite interesting in view of the history of Glivec approval in Brazil and the continuing problems that patients are having in accessing medication in that country. In 2001, when Glivec was being considered for inclusion into Brazil’s NHS (Sistema Unica de Saude or SUS) formulary after its approval by the national drug regulatory agency (Agencia Nacional de Vigilancia Sanitaria, or ANVISA) , accusations were made that Novartis funded and manipulated patient groups to lobby on its behalf to the health ministry, which was engaged in a battle with Novartis over the price of Glivec. Glivec was eventually included in the SUS formulary after the Health Ministry negotiated a price it was willing to accept. The lowered price does not reflect a true discount, but instead an exemption of Glivec from certain import taxes. The 2004 price at which SUS buys Glivec is pegged at approximately $25 USD per 100mg capsule.[3]
The bulk of the Brazilian patients who must depend on SUS for their healthcare, however, not infrequently experience difficulty in receiving Glivec, which is often out of stock at treatment centers around the country. At some public hospitals in southern states (where access generally has been better) the problem has recently been exacerbated by a series of apparently well-planned armed robberies of pharmacies, by thieves specifically demanding that all Glivec supplies be turned over. Authorities speculate that the stolen Glivec is intended for international black markets, as the hospitals’ own patients are receiving the drug at no charge.[4]
Some Brazilian patients have been successful in their quest for Glivec only by filing and winning civil lawsuits against their respective SUS facility. This tactic has been successful, of course, only among the most system-savvy and well-educated.[5] And because Glivec has been approved for the SUS formulary, Brazilian patients are not eligible to participate in the Novartis GIPAP offering. (GIPAP being the Glivec International Patient Assistance Program).

Glivec is not the first drug for whose promotion Novartis has sought to cultivate special relationships with patients in Latin America, although the instances have rarely been reported in the English-language media. Another example is that of cyclosporine, Unitl 1999, Novartis was the sole manufacturer of cyclospsorine ( inherited from Sandoz), a costly anti-rejection drug needed by organ and tissue transplant patients. When generic versions began appearing in 2000, Novartis not only contested their manufacturers’ production rights, but also approached kidney transplant patient groups in Brazil, Costa Rica, and Mexico with offers of education programs and financial support. Patient groups in these countries soon were beseeching their governments to continue to supply them with the Novartis product, citing as evidence studies later shown to be suspect, that the generics were not of the same efficacy.[6]

Present & Future
Despite Brazil’s unresolved socioeconomic and health inequalities, the sheer size of its population and its degree of economic activity, make it a prime market for the multinational pharmas. With increasing levels of education and income, especially in the more populated and prosperous Central-South region, consumer awareness of modern cancer treatments has grown. Brazil is said to be the 9th largest global market for medicines.[7] Novartis and others are also wary of the potential of Brazil’s thriving generic industry (and at the same time preparing to bolster its own generic market share in Brazil),[8] its resurgent popular community activism, and the government’s willingness to exercise its political muscle in the health arena, as seen by its actions on AIDS drugs. The decision by Novartis to withdraw support for an international tropical disease research institute being planned for Manaus, and switch it to Singapore instead, was seen as direct retaliation for the Brazilian government’s breaking of patents on HIV drugs as a positive public health measure.[9] And in a contradictory ideological twist, the recent revelation of a major scandal in Brazil’s Health Ministry, has led to the disclosure that Novartis , among other pharmas, made sizeable campaign contributions to now-President Luis” Lula” Inacio da Silva in 2002, motivated by the desire to defeat contender José Serra, who as Health Minister, who had challenged Novartis over the price of Glivec as a condition for its approval in Brazil.[10]

With a PAP, like this, it remains to be seen just what kind of genuine assistance will be available for Brazilian patients who need Glivec or other imported drugs to treat cancer and other deadly diseases.

When this story was posted in March 2005, this was on the front page of PCOL:

The Peace Corps Library Date: February 7 2005 No: 438 The Peace Corps Library
Peace Corps Online is proud to announce that the Peace Corps Library is now available online. With over 30,000 index entries in over 500 categories, this is the largest collection of Peace Corps related reference material in the world. From Acting to Zucchini, you can use the Main Index to find hundreds of stories about RPCVs who have your same interests, who served in your Country of Service, or who serve in your state.

Top Stories and Breaking News PCOL Magazine Peace Corps Library RPCV Directory Sign Up

March 1: National Day of Action Date: February 28 2005 No: 471 March 1: National Day of Action
Tuesday, March 1, is the NPCA's National Day of Action. Please call your Senators and ask them to support the President's proposed $27 Million budget increase for the Peace Corps for FY2006 and ask them to oppose the elimination of Perkins loans that benefit Peace Corps volunteers from low-income backgrounds. Follow this link for step-by-step information on how to make your calls. Then take our poll and leave feedback on how the calls went.
Coates Redmon, Peace Corps Chronicler  Date: February 26 2005 No: 457 Coates Redmon, Peace Corps Chronicler
Coates Redmon, a staffer in Sargent Shriver's Peace Corps, died February 22 in Washington, DC. Her book "Come as You Are" is considered to be one of the finest (and most entertaining) recountings of the birth of the Peace Corps and how it was literally thrown together in a matter of weeks. If you want to know what it felt like to be young and idealistic in the 1960's, get an out-of-print copy. We honor her memory.

February 26, 2005: This Week's Top Stories Date: February 26 2005 No: 454 February 26, 2005: This Week's Top Stories
Folk-Singer Steve Schuch releases "Trees of Life" 26 Feb
Christopher Bartlett maintains Marine Protected Area 25 Feb
Joseph Frey uses amputation experience to help others 25 Feb
James McCann concerned by maize in Ethiopia 25 Feb
Sen. Obama says PC can help improve diplomacy 24 Feb
PCVs help remove batteries in Belize 24 Feb
Jimmy Carter praises mother's PC service 24 Feb
Craig D. Wandke's lunar passion began in Honduras 23 Feb
Char Andrews discusses her experience with cancer 23 Feb
Beverly Seckinger tells stories through film 23 Feb
J. Tyler Dickovick: As Togo goes, so may go Africa 23 Feb
Andres Hernandez searches for PCV for 40 years 23 Feb
Bulgaria is now like second home to Aaron Wills 22 Feb
Bernadette Roberts to serve as diplomat in Albania 22 Feb
USA Freedom Corps downgraded at White House 22 Feb
Tom Skeldon seeks to control pit bull trade 21 Feb
Gabriela Lena Frank writes music on Dad's PCV service 21 Feb

Make a call for the Peace Corps Date: February 19 2005 No: 453 Make a call for the Peace Corps
PCOL is a strong supporter of the NPCA's National Day of Action and encourages every RPCV to spend ten minutes on Tuesday, March 1 making a call to your Representatives and ask them to support President Bush's budget proposal of $345 Million to expand the Peace Corps. Take our Poll: Click here to take our poll. We'll send out a reminder and have more details early next week.
Peace Corps Calendar: Tempest in a Teapot? Date: February 17 2005 No: 445 Peace Corps Calendar: Tempest in a Teapot?
Bulgarian writer Ognyan Georgiev has written a story which has made the front page of the newspaper "Telegraf" criticizing the photo selection for his country in the 2005 "Peace Corps Calendar" published by RPCVs of Madison, Wisconsin. RPCV Betsy Sergeant Snow, who submitted the photograph for the calendar, has published her reply. Read the stories and leave your comments.
WWII participants became RPCVs Date: February 13 2005 No: 442 WWII participants became RPCVs
Read about two RPCVs who participated in World War II in very different ways long before there was a Peace Corps. Retired Rear Adm. Francis J. Thomas (RPCV Fiji), a decorated hero of the Japanese attack on Pearl Harbor, died Friday, Jan. 21, 2005 at 100. Mary Smeltzer (RPCV Botswana), 89, followed her Japanese students into WWII internment camps. We honor both RPCVs for their service.
Bush's FY06 Budget for the Peace Corps Date: February 7 2005 No: 436 Bush's FY06 Budget for the Peace Corps
The White House is proposing $345 Million for the Peace Corps for FY06 - a $27.7 Million (8.7%) increase that would allow at least two new posts and maintain the existing number of volunteers at approximately 7,700. Bush's 2002 proposal to double the Peace Corps to 14,000 volunteers appears to have been forgotten. The proposed budget still needs to be approved by Congress.
RPCVs mobilize support for Countries of Service Date: January 30 2005 No: 405 RPCVs mobilize support for Countries of Service
RPCV Groups mobilize to support their Countries of Service. Over 200 RPCVS have already applied to the Crisis Corps to provide Tsunami Recovery aid, RPCVs have written a letter urging President Bush and Congress to aid Democracy in Ukraine, and RPCVs are writing NBC about a recent episode of the "West Wing" and asking them to get their facts right about Turkey.

Read the stories and leave your comments.

Some postings on Peace Corps Online are provided to the individual members of this group without permission of the copyright owner for the non-profit purposes of criticism, comment, education, scholarship, and research under the "Fair Use" provisions of U.S. Government copyright laws and they may not be distributed further without permission of the copyright owner. Peace Corps Online does not vouch for the accuracy of the content of the postings, which is the sole responsibility of the copyright holder.

Story Source: Healthy Skepticism

This story has been posted in the following forums: : Headlines; COS - Brazil; Medicine; Patient Assistance Program



Add a Message

This is a public posting area. Enter your username and password if you have an account. Otherwise, enter your full name as your username and leave the password blank. Your e-mail address is optional.